Value of magnetic resonance imaging for diagnosis of LR‑3 and LR-4 lesions coexisting with hepatocellular carcinoma
- PMID: 38834779
- DOI: 10.1007/s00261-024-04338-0
Value of magnetic resonance imaging for diagnosis of LR‑3 and LR-4 lesions coexisting with hepatocellular carcinoma
Abstract
Purpose: To explore which preoperative clinical data and conventional magnetic resonance imaging (MRI) features may indicate the presence of hepatocellular carcinoma (HCC) in HCC patients coexisting with LR-3 and LR-4 lesions.
Methods: HCC Patients coexisting with LR-3 and LR-4 lesions who participated in a prospective clinical trial (XX) were included in this study. Two radiologists independently assessed the preoperative MRI features and each lesion was assigned according to the liver imaging reporting and data system (LI-RADS). The preoperative clinical data were also evaluated. The relative values of these parameters were assessed as potential predictors of HCC for coexisting LR-3 and LR-4 lesions.
Results: We enrolled 102 HCC patients (58.1 ± 11.5 years; 84.3% males) coexisting with 110 LR-3 and LR-4 lesions (HCCs group [n = 66]; non-HCCs group [n = 44]). The presence of restricted diffusion (OR: 18.590, p < 0.001), delayed enhancement (OR: 0.113, p < 0.001), and mild-moderate T2 hyperintensity (OR: 3.084, p = 0.048) were found to be independent predictors of HCC diagnosis. The sensitivity and specificity of the above independent variables for the diagnosis of HCC ranged from 66.7 to 80.3% and 56.8 to 88.6%, respectively. ROC analysis showed that, in discriminating HCC, the AUCs of the above factors were 0.777, 0.686, and 0.670, respectively. Combining these three findings for the prediction of HCC resulted in a specificity greater than 97%, and the AUC further increased to 0.874.
Conclusion: The presence of restricted diffusion, delayed enhancement, and mild-moderate T2 hyperintensity can be useful features for risk stratification of coexisting LR-3 and LR-4 lesions in HCC patients. Trial registration a prospective clinical trial (ChiCTR2000036201).
Keywords: Delayed enhancement; Hepatocellular carcinoma; Preoperative diagnosis; Restricted diffusion.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.BMC Gastroenterol. 2024 Mar 21;24(1):117. doi: 10.1186/s12876-024-03201-2. BMC Gastroenterol. 2024. PMID: 38515017 Free PMC article.
-
LI-RADS version 2018 treatment response algorithm on extracellular contrast-enhanced MRI in patients treated with transarterial chemoembolization for hepatocellular carcinoma: diagnostic performance and the added value of ancillary features.Abdom Radiol (NY). 2024 Sep;49(9):3045-3055. doi: 10.1007/s00261-024-04275-y. Epub 2024 Apr 11. Abdom Radiol (NY). 2024. PMID: 38605217
-
Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.Eur J Gastroenterol Hepatol. 2017 Sep;29(9):1036-1044. doi: 10.1097/MEG.0000000000000916. Eur J Gastroenterol Hepatol. 2017. PMID: 28562394
-
Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Liver Int. 2020 Jun;40(6):1488-1497. doi: 10.1111/liv.14424. Epub 2020 Mar 19. Liver Int. 2020. PMID: 32145134
-
CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.J Am Coll Radiol. 2020 Oct;17(10):1199-1206. doi: 10.1016/j.jacr.2020.06.005. Epub 2020 Jul 5. J Am Coll Radiol. 2020. PMID: 32640250
Cited by
-
CT/MRI technical pitfalls for diagnosis and treatment response assessment using LI-RADS and how to optimize.Abdom Radiol (NY). 2025 May;50(5):2022-2037. doi: 10.1007/s00261-024-04632-x. Epub 2024 Oct 22. Abdom Radiol (NY). 2025. PMID: 39433603 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- 82171897/National Natural Science Foundation of China
- 82371923/National Natural Science Foundation of China
- 2022YX-Q07/Imaging Medical Star Technology Project of Suzhou Medical Association
- 23Y11907400/Science and Technology Commission of Shanghai Municipality
- 202240152/Shanghai Municipal Health Commission
LinkOut - more resources
Full Text Sources
Medical